Lipella reports positive Phase 2a results for LP-10 in hemorrhagic cystitis

LIPELLA PHARMACEUTICALS INC.

All 13 subjects tolerated LP-10 without product-related serious adverse events.
Dose response observed: decreased hematuria, cystoscopic bleeding/ulceration, improved urinary symptoms.
Responder analysis: complete response in 3 subjects, partial in 7, no response in 3 subjects.
LP-10 has Orphan Drug Designation; no FDA-approved treatment exists for hemorrhagic cystitis.
CEO to present results at Biotech Showcase 2023 on January 11, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.